Advertisement

Urologic morbidity associated with placenta accreta spectrum surgeries: single-center experience with a multidisciplinary team

Published:August 12, 2021DOI:https://doi.org/10.1016/j.ajog.2021.08.010

      Background

      Hysterectomy for placenta accreta spectrum may be associated with urologic morbidity, including intentional or unintentional cystostomy, ureteral injury, and bladder fistula. Although previous retrospective studies have shown an association between placenta accreta spectrum and urologic morbidities, there is still a paucity of literature addressing these urologic complications.

      Objective

      We sought to report a systematic description of such morbidity and associated factors.

      Study Design

      This was a retrospective study of all histology-proven placenta accreta spectrum deliveries in an academic center between 2011 and 2020. Urologic morbidity was defined as the presence of at least one of the following: cystotomy, ureteral injury, or bladder fistula. Variables were reported as median (interquartile range) or number (percentage). Analyses were made using appropriate parametric and nonparametric tests. Multinomial regression analysis was performed to assess the association of adverse urologic events with the depth of placental invasion.

      Results

      In this study, 58 of 292 patients (19.9%) experienced urologic morbidity. Patients with urologic morbidity had a higher rate of placenta percreta (compared with placenta accreta and placenta increta) than those without such injuries. Preoperative ureteral stents were placed in 54 patients (93.1%) with and 146 patients (62.4%) without urologic injury (P=.003). After adjusting for confounding variables, multinomial regression analysis revealed that the odds of having adverse urologic events was 6.5 times higher in patients with placenta percreta than in patients with placenta accreta.

      Conclusion

      Greater depth of invasion in placenta accreta spectrum was associated with more frequent and severe adverse urologic events. Whether stent placement confers any protective benefit requires further investigation.

      Key words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cahill A.G.
        • et al.
        • Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine
        Placenta accreta spectrum.
        Am J Obstet Gynecol. 2018; 219: B2-16
        • Solheim K.N.
        • Esakoff T.F.
        • Little S.E.
        • Cheng Y.W.
        • Sparks T.N.
        • Caughey A.B.
        The effect of cesarean delivery rates on the future incidence of placenta previa, placenta accreta, and maternal mortality.
        J Matern Fetal Neonatal Med. 2011; 24: 1341-1346
        • Eller A.G.
        • Porter T.F.
        • Soisson P.
        • Silver R.M.
        Optimal management strategies for placenta accreta.
        BJOG. 2009; 116: 648-654
        • Gungorduk K.
        • Asicioglu O.
        • Celikkol O.
        • Sudolmus S.
        • Ark C.
        Iatrogenic bladder injuries during caesarean delivery: a case control study.
        J Obstet Gynaecol. 2010; 30: 667-670
        • Hoffman M.S.
        • Karlnoski R.A.
        • Mangar D.
        • et al.
        Morbidity associated with nonemergent hysterectomy for placenta accreta.
        Am J Obstet Gynecol. 2010; 202: 628.e1-628.e5
        • Norris B.L.
        • Everaerts W.
        • Posma E.
        • et al.
        The urologist’s role in multidisciplinary management of placenta percreta.
        BJU Int. 2016; 117: 961-965
        • Woldu S.L.
        • Ordonez M.A.
        • Devine P.C.
        • Wright J.D.
        Urologic considerations of placenta accreta: a contemporary tertiary care institutional experience.
        Urol Int. 2014; 93: 74-79
        • Shamshirsaz A.A.
        • Fox K.A.
        • Salmanian B.
        • et al.
        Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach.
        Am J Obstet Gynecol. 2015; 212: 218.e1-218.e9
        • Erfani H.
        • Fox K.A.
        • Clark S.L.
        • et al.
        Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team.
        Am J Obstet Gynecol. 2019; 221: 337.e1-337.e5
        • Shamshirsaz A.A.
        • Fox K.A.
        • Erfani H.
        • et al.
        Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time.
        Am J Obstet Gynecol. 2017; 216: 612.e1-612.e5
        • Shamshirsaz A.A.
        • Fox K.A.
        • Erfani H.
        • et al.
        Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta.
        Obstet Gynecol. 2018; 131: 234-241
        • Fox K.A.
        • Shamshirsaz A.A.
        • Carusi D.
        • et al.
        Conservative management of morbidly adherent placenta: expert review.
        Am J Obstet Gynecol. 2015; 213: 755-760
        • Salman L.
        • Aharony S.
        • Shmueli A.
        • Wiznitzer A.
        • Chen R.
        • Gabbay-Benziv R.
        Urinary bladder injury during cesarean delivery: maternal outcome from a contemporary large case series.
        Eur J Obstet Gynecol Reprod Biol. 2017; 213: 26-30
        • Nieto-Calvache A.J.
        • López-Girón M.C.
        • Messa-Bryon A.
        • et al.
        Urinary tract injuries during treatment of patients with morbidly adherent placenta.
        J Matern Fetal Neonatal Med. 2021; 34: 3140-3146